Michael Eggenberg - 15 Aug 2022 Form 4 Insider Report for Xtant Medical Holdings, Inc. (XTNT)

Role: Director, 10%+ Owner
Signature: /s/ Amy Culbert, attorney-in-fact
Issuer symbol: XTNT
Transactions as of: 15 Aug 2022
Net transaction value: $0
Form type: 4
Filing time: 17 Aug 2022, 16:12:10 UTC
Previous filing: 17 Aug 2021
SEC filing: View on sec.gov

Key filing fact

Michael Eggenberg filed Form 4 for Xtant Medical Holdings, Inc. (XTNT) on 17 Aug 2022.

Key facts

This page summarizes Michael Eggenberg's Form 4 filing for Xtant Medical Holdings, Inc. (XTNT).
1 reported transaction and 0 derivative rows are listed below.
Filing timestamp: 17 Aug 2022, 16:12.

Change

Previous filing in this sequence was filed on 17 Aug 2021.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

See Original Filing

Reported transactions

XTNT transaction

Common Stock, $0.000001 par value

Award

Transaction value: $0
Shares: +215,415
Change %
Price: $0.000000
Shares after: 215,415
Date: 15 Aug 2022
Ownership: Direct
Footnotes: F1, F2

XTNT holding

Common Stock, $0.000001 par value

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 56,004,974
Date: 15 Aug 2022
Ownership: See Footnotes
Footnotes: F3, F4

XTNT holding

Common Stock, $0.000001 par value

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 17,109,618
Date: 15 Aug 2022
Ownership: See Footnotes
Footnotes: F4, F5

^* indicates a reported price that failed the local validity check.

Explanation of Responses:

Id	Content
F1	These shares are subject to restricted stock unit awards granted under the Xtant Medical Holdings, Inc. Amended and Restated 2018 Equity Incentive Plan, and vest and become issuable on August 15, 2023, conditioned upon the Reporting Person remaining a director of Xtant through the vesting date.
F2	The Reporting Person's Form 4 report filed on August 17, 2021 previously reported 120,549 shares that were subject to unvested restricted stock unit awards. These shares have vested and were transferred to each of ROS Acquisition Offshore LP ("ROS Acquisition") and OrbiMed Royalty Opportunities II, LP ("ORO II").
F3	These securities are held of record by ROS Acquisition. OrbiMed Advisors LLC ("Advisors"), a registered investment adviser under the Investment Advisors Act of 1940, as amended, is the investment manager of ROS Acquisition. By virtue of such relationships, Advisors may be deemed to have voting and investment power with respect to the securities held by ROS Acquisition as noted above and as a result may be deemed to have beneficial ownership over such securities. Advisors exercises its voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the securities held by ROS Acquisition.
F4	Each of OrbiMed ROF II LLC ("ROF II"), Advisors and the Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its or his pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for the purposes of Section 16 of the Exchange Act, or for any other purposes. The Reporting Person is an employee of Advisors.
F5	These securities are held of record by ORO II. ROF II is the general partner of ORO II, and Advisors is the managing member of ROF II. By virtue of such relationships, Advisors and ROF II may be deemed to have voting and investment power with respect to the securities held by ORO II as noted above and as a result may be deemed to have beneficial ownership over such securities. Advisors exercises its voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the securities held by ORO II.